| INTRODUCTION
Elevated blood pressure (BP) is a leading risk factor for premature death, stroke, and heart disease worldwide. [1] [2] [3] A broad armament of evidence-based treatment options as well as guidelines providing the latest evidence on how to use these different treatment options exist. [3] [4] [5] [6] [7] Nevertheless, there is suspicion that a considerable proportion of patients diagnosed with hypertension worldwide do not receive appropriate treatment. Different studies have found a substantial gap between guideline recommendations and the actual treatment of hypertension in patients. [8] [9] [10] [11] [12] [13] [14] [15] This gap is often referred to as the evidence-performance gap (EPG). 16, 17 Approximately 60% or more patients with hypertension worldwide, especially patients treated in primary care settings, might be affected by the EPG. These previous studies used the BP threshold of 140/90 mm Hg as a single criterion for appropriate treatment. Consequently, all patients with a BP ≥140/90 mm Hg without treatment, disregarding their overall cardiovascular risk (CVR), were defined as being affected by the EPG.
Because comorbidities and other CVR factors in addition to hypertension are frequent in real-life patients, especially in the primary care setting, the integration of comorbidities and CVR factors into the assessment is important.
18-21
Recent studies support the recommendation to shift focus from rigid BP thresholds to patients' overall CVR to facilitate an individualized risk-adjusted assessment whenever deciding on hypertension treatment. A possible explanation for the EPG is that primary care physicians (PCPs) adapt guideline recommendations to the needs of their real-life patients, a finding that has been shown in diabetes management. 22 Thus, EPGs might rather be explained by an individualized risk-adjusted assessment than by low adherence to guidelines. 23 The However, the proportion of patients with hypertension who qualify for treatment according to these guidelines remains unknown, as it is true for the proportion of patients affected by the EPG.
We hypothesize that the risk-adjusted approach will result in a smaller proportion of patients who qualify for treatment; thus, the EPG will decrease.
| METHODS
This cross-sectional study used data collected from electronic medi- 
| Patients
All patients registered in the FIRE database between January 2009 and August 2015 were assessed for the eligibility criterion hypertension.
The definition of hypertension was based on the occurrence of at least one of the following criteria (which were searched for in the following hierarchically order):
• more than two BP measurements ≥140/90 mm Hg or
• at least one recorded ICPC-2 coding (K85 "elevated blood pressure," K86 "hypertension uncomplicated," K87 "hypertension complicated") or
• at least two prescriptions for antihypertensive drugs according to ATC coding as validated by Lamers and colleagues 29 (C02 "antihypertensives," C03A "low-ceiling diuretics, thiazides," C03EA01 "hydrochlorothiazide and potassium-sparing agents," C07 "beta-blocking agents," C08 "calcium channel blockers," C09A "ACE inhibitors, plain,"
C09B "ACE inhibitors, combinations") and ATC coding of angiotensin II receptor antagonists (C09C "angiotensinogen II antagonists, plain,"
C09D "angiotensinogen II antagonists, combinations").
Patients who had fewer than two BP measurements (regardless of the measured value [this was possible as eligible patients had to meet only one and not all three inclusion criteria to be eligible]), fewer than two PCP consultations, were younger than 18 years, or pregnant were excluded.
Patients' individual observation period was defined using an inclusion and an end date. The first visit date on which a patient met one of the three inclusion criteria was used as the inclusion date. The end date was the date of the latest visit a BP measurement was made.
ICPC-2 codes were used if they occurred only once, as these codes were based on best medical practice by participating PCPs who did the coding by themselves. ATC codes were used if they occurred at least twice to avoid prescription errors. We used the latest available data for changing parameters (eg, laboratory data or demographic data such as weight) going backward starting at the end date.
| Baseline characteristics
The following baseline characteristics of included patients were assessed based on medical record entries: "age," "antihypertensive drugs," "concomitant nonantihypertensive drugs," "concomitant chronic diseases," "BP measurements," "risk factors," and "asympto- 
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Patients were stratified to these groups based on the mean value of all recorded BP measurements. As recommended by the 2013 ESC/ ESH guidelines, stratification to a specific hypertension grade group was based on the higher level, regardless of whether it was SBP or DBP. If two BP measurements were available from the same visit, we used the mean of the two available values.
| Stratification according to CVR categories (risk-adjusted approach)
As recommended by the 2013 ESH/ESC guidelines, we established eight CVR categories: average, low, low-moderate, moderate, moderate-high, high, high-very high, and very high depending on the patients' hypertension grade group and number of existing risk factors, asymptomatic organ damage, and established diseases (see Figure 1 for details). Therefore, we searched each patient's latest medical record for ICPC-2 diagnoses, medication lists/ATC codes, and laboratory results (Table 1 ).
| Treatment criteria
All patients stratified to hypertension grade ≥1 group qualified for drug treatment according to the standardized BP approach.
All patients with hypertension grade ≥1 group with a CVR category of at least "high" qualified for drug treatment according to the risk-adjusted approach.
Exceptions within the risk-adjusted approach apply to young patients with isolated systolic hypertension (ISH) and elderly patients. In the context of ISH, patients 30 years or younger were determined as "young." observation period was subject to change, patients included in the first as well as the last years were not included in this sensitivity analysis.
| Statistical analysis
Continuous variables are presented as means and standard deviations (SDs) and categorical data as frequencies and percentages. We used Walds interval to calculate the confidence interval (CI). 36 Data analysis was performed using R statistics software (version 3.2.0; R Foundation, Vienna, Austria). 
| RESULTS
Until August 2015, 264 641 primary care patients were registered in the FIRE database. All patients were assessed for the eligibility criterion hypertension and 48 602 were defined as eligible. Of these, 20 236 patients were excluded because they had fewer than two BP measurements available, 312 patients had fewer than two PCP consultations, 5613 patients were younger than 18 years, and seven patients were pregnant. Data on the remaining 22 434 patients with hypertension were included in the analysis (Figure 2 ).
The average age of included patients was 66.4 years and 50.7%
were male. The average observation period for the individual patient was 2.7 years. During observation, on average 9.7 BP measurements per patient were performed, corresponding to an average of 3.7 BP measurements per patient per year. In addition to hypertension, patients had a mean of 4.8 concomitant chronic diseases and took 5.9
concomitant nonantihypertensive drugs. Detailed baseline characteristics are shown in Table 2 . The latter were therefore identified as being affected by the EPG (Figure 3 ).
| Standardized BP approach

| Risk-adjusted approach
Based on the CVR categories, 44.6% (95% CI, 43.6-45.6) of all patients qualified for drug treatment. A total of 33.9% (95% CI, 32.8-34.9) received a drug as recommended, while 10.8% (95% CI, 9.5-12.0) received no drugs although they qualified for treatment.
The latter were therefore identified as being affected by the EPG (Figure 3 ).
| Difference between approaches
The proportion of patients affected by the EPG differed by 12.2%
(95% CI, 10.9-13.4) depending on the approach used. 8.1% (1816/22 434) were assigned to the "very high" CVR category.
| Further analysis
Results of stratification of patients to different CVR categories are
shown in Figure 1 .
The age stratification of all 2416 patients affected by the riskadjusted EPG approach showed that 11.1% (266/2416) of these patients were 60 years or younger, while 88.9% (2150/2416) were older than 60 years ( Figure 4 ).
Among patients younger than 60 years, three patients were identified as being affected by ISH.
Sensitivity analysis splitting the 6-year observation period into two periods of 3 years each showed no relevant difference in clinical practice concerning our main outcome of "appropriateness of hypertension treatment."
| DISCUSSION
In this study, we applied two different approaches to data of patients with hypertension treated in Swiss primary care to evaluate the pro- Patients with hypertension eligible due to meeting at least one of three inclusion criteria:
Two BP measurements >140/90 mm Hg (n=22'762) Diagnose of hypertension (ICPC2 code) (n=8'533) Antihypertensive Medication (ATC code) (n=17'307)
n=22'434
Patients included
Risk-adjusted approach
Analysis according to cardiovascular risk categories
n=26'168
Patients excluded due to exclusion criteria:
Only one BP measurement available (n=20'236)* Only one consultation with primary care physician (n=312)
Age younger than 18 years (n=5'613) Pregnancy (n=7)
n=22'434
Standardized BP approach
Analysis according to BP threshold of 140/90 mm Hg
n=264'641
Patients registrated in FIRE database were assessed for eligibility affected by the EPG decreased from 23.0% using the standardized BP approach to 10.8% using the risk-adjusted approach, resulting in a difference of 12.2%.
Our results using the standardized BP approach are comparable to previous studies that only used the standardized BP approach and neglected patients' individual CVR factors. Some of these studies described a decrease of the EPG over time but attributed it to reasons such as a healthier lifestyle, increase of drug treatment, or higher awareness of hypertension. 10, 11, 13, 14, 37, 38 Scheltens and colleagues 12 were the first and only authors who used a more individualized approach estimating the EPG in hypertension management based on the Framingham risk function. However, they applied this approach only to a small (n=292) and special subgroup of patients with hypertension who were free from cardiovascular disease and had an average age of 38 years. Moreover, this approach was based on a number of assessment criteria that is currently considered outdated. 12 Recently, Navar-Boggan and colleagues 39 demonstrated that the introduction of a new guideline for hypertension management in the United States significantly changed the proportion of patients who qualified for treatment.
Applying the 2013 ESH/ESC guidelines, we are now the first to use a risk-adjusted approach. This risk-adjusted approach reduced the EPG by more than 50%. A more detailed analysis of the proportion of patients (10.8%) affected by the EPG using the risk-adjusted approach showed that the majority (88.9%) of patients was older than 60 years when stratified by age. Unfortunately, specifications of terms concerning age such as "elderly" are vague and differ considerably depending on the source. Obviously, additional treatment as well as concomitant chronic disease will complicate the decision. 41 In this study, patients had a mean → → the intensive-treatment group experienced significantly higher rates of some adverse events. 42, 43 These results, supported by data from a large meta-analysis, will influence future guidelines and stress the importance of risk adjustment and patient-centeredness. 
| Strengths und limitations
In our dataset, the prevalence of hypertension is seemingly low compared with other studies in the primary care setting. Our data were extracted from routinely collected data from medical records. Therefore, they are subject to the usual limitations of routine data. 48, 49 We assessed patients' CVR profile according to the 2013 ESH/ESC guidelines, but some variables (ie, smoking, abdominal obesity, family history for premature cardiovascular diseases, and indicators for asymptomatic organ damage) were limited or not available in our dataset. However, PCPs base their daily decisions on the same variables as we did when extracting data from their medical records.
Thus, these data are the best available proxy to measure the actual medical care situation of primary care patients with hypertension to date. A prospective study in this setting would be a disruption of daily practice and prone to the Hawthorne effect. Further, the cross-sectional design of the study may be seen as a limitation, but it has to be acknowledged that data from previous studies is derived from surveys where data collection usually takes place on a single day. In contrast, we evaluated patients who qualified for drug treatment based on the whole available record history.
This study of patients with hypertension in Swiss primary care is of international value because hypertension treatment is an eminent problem in health systems worldwide and the majority of patients with hypertension are treated in this setting. 8, 9, 12, 42 Most likely, our data cannot be generalized to other care settings, but countries with an equal health system should take these results as a suggestion to revisit previous EPG estimations. Switzerland serves as a good example of an industrialized country with an insurance-based healthcare system with a fee-for-service reimbursement and mostly free choice of doctors-a model that can also be found in other countries, eg, Austria, France, Germany, and parts of the United States. The estimation of the actual risk-adjusted EPG in Swiss primary care will thus allow an extrapolation of the EPG in these countries.
| CONCLUSIONS
Application of the risk-adjusted approach as recommended by the 2013 ESH/ESC guidelines reduced the EPG by more than 50%.
This demonstrates the major impact of risk adjustment and highlights the need for a patient-centered approach in the treatment of hypertension.
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